Ceftobiprole Approval Status

  • FDA approved: No
  • Generic name: ceftobiprole
  • Company: Johnson Pharmaceutical Research & Development, L.L.C.
  • Treatment for: Skin and Structure Infection

Ceftobiprole is an investigational antibiotic, for the treatment of complicated skin and skin structure infections (cSSSI), including diabetic foot infections, in adults.

FDA Approval Status for ceftobiprole

DateArticle
Dec 30, 2009FDA Issues Complete Response Letter for Ceftobiprole
Sep  3, 2009FDA accepts for review the Complete Response submission to ceftobiprole NDA
Nov 26, 2008FDA Issues Complete Response Letter for Ceftobiprole for Treatment of Complicated Skin Infections
Sep 15, 2008FDA accepts for review the Complete Response to ceftobiprole NDA Approvable Letter
Mar 18, 2008FDA Issues Approvable Letter for Ceftobiprole for Treatment of Complicated Skin Infections
Feb 13, 2008FDA Published Today That It Will Not Hold an Advisory Committee Meeting on Ceftobiprole in the Treatment of Complicated Skin and Skin Structure Infections
Jan 10, 2008Basilea Announces Review of Ceftobiprole NDA at FDA Anti-Infective Drugs Advisory Committee Meeting
Jul 18, 2007U.S. FDA and European EMEA Accept Registration Applications for Ceftobiprole, Novel Anti-MRSA Broad-Spectrum Cephalosporin
May 18, 2007New Drug Application Submitted For Novel Investigational Antibiotic Ceftobiprole

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide
(web3)